Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming Soon - May 2019
Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. There have been significant investments in this space, notably including multiple deals made through the Janssen Human Microbiome Institute and several multimillion dollar IPOs, including Seres Therapeutics and Evelo Biosciences. However, no microbiome-based therapy has yet received an FDA approval, although FMT is widely accepted for use in recurrent C. difficile infections and proprietary microbiome-based candidates are proceeding to Phase III clinical trials. With new therapies entering Phase II clinical trials, and more in early-phase research and development, it is becoming increasingly important to understand the potential of this emerging group of therapies.
· How do physicians familiar with microbiome research evaluate the potential of microbiome-based therapies, and what therapies are seen as most promising?
· What therapy areas will benefit from microbiome-based therapies? How will such therapies fit into the existing treatment algorithms?
· Will particular mechanisms of administration be more successful? Will live bacteria or microbiome-derived small molecules be effective?
· What potential hurdles will such therapies face in the market? How do physicians anticipate regulatory agencies will respond?
United States, EU5
High-level overview of relevant epidemiological figures for selected indications. FORECAST Drug-level sales in 2024 and 2029
Phase II: 5 drugs; coverage of select preclinical and Phase I products
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This special report is based on a modified Disease Landscape & Forecast template, with abbreviated epidemiological data and current treatment analysis, but including expanded content covering ongoing early-phase research and regulatory concerns specific to live bacterial products.
Already a Client? Log in to access this report.
Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.